Emerging data suggest Retatrutide , a dual agonist targeting both incretin and another hormone, may offer a notable step forward for obesity management . Preliminary patient trials have shown considerable reductions in visceral fat , potentially surpassing existing obesity treatments. Despite this, more assessment is necessary to fully assess its s